AzTrials
AzTrials

PFIC1Phase 3PEDFIC 1NCT03566238

This Study Will Investigate the Efficacy and Safety of A4250 in Children With PFIC Types 1 or 2

A Phase 3 study testing A4250 (odevixibat) in people with PFIC1 and PFIC2, run by Albireo at 45 sites in 15 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2. Read more about this study

Who is it for?
Ages 6 months to 18 years
Conditions the study is for
PFIC1, PFIC2
What is being tested?
A4250 (odevixibat)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
62 participants
Where
45 sitesin 15 countries
Study dates
16 May 2018to 28 Jul 2020
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 months to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • A male or female participant with a clinical diagnosis of PFIC Type 1 or 2 and with a body weight above 5 kg
  • Participant must have clinical genetic confirmation of PFIC-1 or PFIC-2
  • Participant must have elevated serum bile acid (s-BA) concentration
  • Participant must have history of significant pruritus and a caregiver reported observed scratching in the eDiary
  • Participant and/or legal guardian must sign informed consent (and assent) as appropriate.
  • Participants will be expected to have a consistent caregiver(s) for the duration of the study
  • Caregivers and age-appropriate participants (≥8 years of age) must be willing and able to use an eDiary device as required by the study

Who cannot join

  • Participant with pathologic variations of the ABCB11 gene that predict complete absence of the bile salt export pump (BSEP) protein
  • Participant with past medical history or ongoing presence of other types of liver disease including, but not limited to, the following:
  • Biliary atresia of any kind
  • Benign recurrent intrahepatic cholestasis, indicated by any history of normal s BAs
  • Suspected or proven liver cancer or metastasis to the liver on imaging studies
  • Histopathology on liver biopsy that is suggestive of alternate non-PFIC related etiology of cholestasis
Show all 14Show fewer
  • Participant with past medical history or ongoing chronic diarrhea
  • Any participant with suspected or confirmed cancers except for basal cell carcinoma
  • Participant with a past medical history of chronic kidney disease with an impaired renal function and a glomerular filtration rate <70 mL/min/1.73 m^2
  • Participant with surgical history of disruption of the enterohepatic circulation (biliary diversion surgery) within 6 months prior to start of Screening Period
  • Participant has had a liver transplant or a liver transplant is planned within 6 months of randomization
  • Decompensated liver disease
  • Participant suffers from uncontrolled, recalcitrant pruritic condition other than PFIC
  • Participant who has been previously treated with an IBAT inhibitor whose pruritus has not responded to treatment

Trial locations and contacts

45 sites in 15 countries.

45 sites in 15 countries

United States12 sites
  • Emory University School of Medicine

    Atlanta, Georgia, 30329

  • Johns Hopkins School of Medicine

    Baltimore, Maryland, 21287

  • Cleveland Clinic

    Cleveland, Ohio, 44195

  • Children's Hospital Colorado

    Denver, Colorado, 80045

  • Baylor College of Medicine - Texas Children's Liver Center

    Houston, Texas, 77030

  • Children's Hospital Los Angeles

    Los Angeles, California, 90027

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029

  • Columbia University Medical Center - Presbyterian Hospital Building

    New York, New York, 10032

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104

  • Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania, 15224

  • University of California, San Francisco

    San Francisco, California, 94143

  • Washington University School of Medicine

    St Louis, Missouri, 63110

Other trials in United States

Turkey (Türkiye)5 sites
  • Gazi University

    Ankara

  • Hacettepe University Faculty of Medicine

    Ankara

  • Akdeniz University

    Antalya

  • Istanbul University Medical Faculty

    Istanbul

  • Inonu University Medical Faculty

    Malatya

Other trials in Turkey (Türkiye)

France4 sites
  • University and Pediatric Hospital of Lyon

    Bron

  • Universite Paris SUD - Hopitaux Universitaires Paris-Sud - Hopital Bicetre

    Le Kremlin-Bicêtre

  • Hospital de la Timone

    Marseille

  • Hospital Necker-Enfants maladies

    Paris

Other trials in France

Germany3 sites
  • Uniklinikum Essen- Kinderklinik II

    Essen

  • Medizinische Hochschule Hannover

    Hanover

  • Kinderklinik Tübingen, Universitätsklinikum Tübingen

    Tübingen

Other trials in Germany

Israel3 sites
  • Rambam Medical Centre

    Haifa

  • Shaare-Zedek Mc

    Jerusalem

  • Schneider Children's Medical Center Of Israel

    Petah Tikva

Other trials in Israel

Italy3 sites
  • Azienda Ospedaliera Papa Giovanni XXIII

    Bergamo

  • University Hospital Of Padova

    Padova

  • Ospedale Regina Margherita

    Torino

Other trials in Italy

United Kingdom3 sites
  • Birmingham Women's and Children's NHS Foundation Trust

    Birmingham

  • Leeds General Infirmary

    Leeds

  • Institute of Liver Studies - Kings College Hospital

    London

Other trials in United Kingdom

Belgium2 sites
  • UZ Leuven

    Leuven

  • Cliniques Universitaires Saint-Luc

    Woluwe-Saint-Lambert

Other trials in Belgium

Canada2 sites
  • The Hospital for Sick Children

    Toronto

  • British Columbia Children's Hospital

    Vancouver

Other trials in Canada

Netherlands2 sites
  • University Medical Center Groningen

    Groningen

  • Universitair Medisch Centrum (UMC) Utrecht

    Utrecht

Other trials in Netherlands

Spain2 sites
  • Hospital Universitari Vall d'Hebron

    Barcelona

  • Hospital Universitario La Paz

    Madrid

Other trials in Spain

Australia1 site
  • The Royal Children's Hospital

    Melbourne

Other trials in Australia

Poland1 site
  • Instytut Pomnik - Centrum Zdrowia Dziecka

    Warsaw

Other trials in Poland

Saudi Arabia1 site
  • King Faisal Specialist Hospital & Research Centre

    Riyadh, 11211

Other trials in Saudi Arabia

Sweden1 site
  • Astrid Lindgren Children's Hospital, Karolinska University Hospital

    Solna

Other trials in Sweden

About this study

Official title: A Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study to Demonstrate Efficacy and Safety of A4250 in Children With Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 1)

Double blind, randomized, placebo controlled, Phase 3 study to investigate the efficacy and safety of low doses and high doses of A4250 compared to placebo in children with progressive familial intrahepatic cholestasis (PFIC) types 1 and 2.

Read the detailed description

Up to 50 sites in the following countries will take part in this study:

Australia, Belgium, Canada, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden, Turkey, United Kingdom, United States, and Saudi Arabia

Conditions
PFIC1, PFIC2
Being tested
A4250 (odevixibat), Placebo
Keywords
Pediatric, Cholestasis
Medical subject headings
Cholestasis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • A4250 (odevixibat)Drug

    A4250 is a small molecule and selective inhibitor of ileal bile acid transporter (IBAT).

  • PlaceboDrug

    Placebo identical in appearance to active drug (A4250).

Study groups in NCT03566238
Study groupRoleWhat they receive
A4250 low doseExperimentalCapsules for oral administration (40 ug/kg) once daily for 24 weeks
Receives: Drug: A4250 (odevixibat)
A4250 high doseExperimentalCapsules for oral administration (120 ug/kg) once daily for 24 weeks
Receives: Drug: A4250 (odevixibat)
PlaceboPlacebo comparatorCapsules for oral administration (to match active) once daily for 24 weeks
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of Treatment

    Fasting s-BA baseline was calculated as the average of the last 2 values prior to the first dose. The end value was the average of the values at Weeks 22 and 24 after the start of double-blind treatment. Participants who had at least 70% reduction in fasting s-BA from baseline to the end of treatment or reached <=70 mcmol/L after 24 weeks of treatment were considered as responder. Participants with missing average at the end of treatment were classified as non-responder. Percentages are rounded to hundredth decimal.

    Measured: From Baseline (Day 1) up to Week 24

  2. Percentage of Positive Pruritus Assessments at the Participant Level Based on the Albireo Observer-Reported Outcome (ObsRO) Instrument Over the 24-Week Treatment Period

    A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100.

    Measured: From Baseline (Day 1) up to Week 24

Secondary outcomes (11)
  1. Change From Baseline in Fasting Serum Bile Acid at Weeks 12 and 24

    Blood samples for analysis of s-BA were drawn at all visits. Participants were to fast (water intake only was permissible) for at least 4 hours prior to the collection of samples. Exceptions could be made for infants <12 months of age if they were unable to fast for the full 4 hours. Baseline was the average of the last 2 non-missing values of fasting s-BA concentration prior to the first dose of study treatment.

    Measured: Baseline (Day 1) and Weeks 12 and 24

  2. Change From Baseline in Serum Alanine Aminotransferase (ALT) Concentration at Weeks 12 and 24

    Blood samples were collected to determine the ALT concentration. Baseline was the last available assessment before the first dose of study treatment.

    Measured: Baseline (Day 1) and Weeks 12 and 24

  3. Change From Baseline in Growth Parameters at Weeks 12 and 24

    The change in the growth parameters was assessed using linear growth deficit [height (centimeter), weight (kilogram) and body mass index (BMI) (kg/meter square)] compared to standard growth curve (Z-score) calculated by using the software or methods from the centers for disease control (CDC) website for participants with age >=2 years old and from the world health organization website for participants with age <2 years old. Participants whose accurate age was not available, Z-score was not calculated. A Z-score indicated how many standard deviation's (SD) a participant's measurement (like height, weight and BMI), was from the average for their age and sex. A Z-score of 0 represents the median or 50th percentile, while positive or negative values show how far above or below average a measurement was. Baseline was the last available assessment before the first dose of study treatment.

    Measured: Baseline (Day 1) and Weeks 12 and 24

  4. Percentage of Responders for Pruritus Assessments Based on Bi-Weekly and Monthly Scores Using the Albireo Observer-Reported Outcome Instrument at Weeks 12 and 24

    The responder for pruritus scores was defined as a participant who achieved at least a 1-point reduction in the ObsRO pruritus score. Percentages are rounded to hundredth decimal.

    Measured: Weeks 12 and 24

  5. Change From Baseline in Sleep Parameters Based on the Albireo Observer-reported Outcome Instrument Over the 24-Week Treatment Period

    The sleep disturbance were recorded twice daily via the electronic diary (eDiary). Participants and/or caregivers completed the eDiary every day in the morning and in the evening. The morning diary was completed shortly after the participant woke up and was used to record nighttime itching and scratching severity, aspects of sleep disturbance, and tiredness upon waking (AM scores). The evening/bedtime diary was completed just before the participant went to bed and recorded participant's itching and scratching severity, and tiredness during the day (PM scores). Both morning and bedtime diaries included Albireo ObsRO and PRO items. Baseline was the average of 14-day scores before the first dose of study treatment.

    Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24

  6. Change From Baseline in Sleep Parameters Based on the Albireo Patient-Reported Outcome (PRO) Instrument Over the 24-Week Treatment Period

    The ObsRO and electronic diary (eDiary) PRO scale called PRUCISION was used to assess pruritus and sleep outcomes. Participants and/or caregivers completed the eDiary every day in the morning (AM scores) and in the evening (PM scores). Specifically, for difficulty falling or staying asleep, the following 2 respective questions were asked in the Morning Daily eDiary: 1) How hard was it to fall asleep last night because of your itching. and 2) How hard was it to stay asleep last night because of your itching. The PRO was a 5-point scale, and scores ranged from 0 (no itching) to 28 (the worst itching), where higher scores indicated a greater amount of itching, sleep disturbance, and tiredness. No subscales were used. Change in sleep parameters measured with the Albireo PRO and ObsRO instruments by each 4-week interval over the 24-week treatment period was assessed. Baseline was the average of 14-day scores before the first dose of study treatment.

    Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24

  7. Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period

    A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.

    Measured: From Baseline (Day 1) up to Week 24

  8. Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo PRO Instrument Over the 24-Week Treatment Period

    A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo PRO instrument, only participants >=8 years of age completed the Albireo PRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.

    Measured: From Baseline (Day 1) up to Week 24

  9. Percentage of Individual Assessments Meeting the Definition of a Positive Pruritus Assessment at the Participant Level Using the Albireo ObsRO Instrument Over the 24-Week Treatment Period

    A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO instrument. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100. At each assessment, the AM or PM score was compared to the baseline AM or PM average, respectively.

    Measured: Baseline (Day 1) and Weeks 1 to 4, Weeks 5 to 8, Weeks 9 to 12, Weeks 13 to 16, Weeks 17 to 20, and Weeks 21 to 24

  10. Number of Participants Underwent Biliary Diversion Surgery and Liver Transplantation

    The number of participants underwent biliary diversion surgery and liver transplantation was determined.

    Measured: From Baseline (Day 1) up to Week 24

  11. Number of Participants Achieved Positive Pruritus Assessment for >50% of the Time Based on the Albireo ObsRO and PRO Instruments Over the 24-Week Treatment Period

    A positive pruritus assessment was defined as a scratching score of <=1 or at least 1 point drop from baseline based on the Albireo ObsRO and PRO instruments. The percentage of positive pruritus assessment was calculated as the number of positive pruritus assessments divided by the total number of reported assessments only when more than 50% of planned assessment recorded by each participant multiplied by 100.

    Measured: From Baseline (Day 1) up to Week 24

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Jun 2018
  2. Study start16 May 2018
  3. Primary completion27 Jul 2020
  4. Study completion28 Jul 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double-Blind, Randomized, Placebo-Controlled
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
62 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03566238
Sponsor's protocol ID
A4250-005
Acronym
PEDFIC 1
Status last verified
Nov 2025
First submitted
25 May 2018
Last updated
28 Nov 2025
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No

Publications

  • Gwaltney C, Ivanescu C, Karlsson L, Warholic N, Kjems L, Horn P. Validation of the PRUCISION Instruments in Pediatric Patients with Progressive Familial Intrahepatic Cholestasis. Adv Ther. 2022 Nov;39(11):5105-5125. doi: 10.1007/s12325-022-02262-7. Epub 2022 Sep 6.

    PubMed 36066745
  • Thompson RJ, Arnell H, Artan R, Baumann U, Calvo PL, Czubkowski P, Dalgic B, D'Antiga L, Durmaz O, Fischler B, Gonzales E, Grammatikopoulos T, Gupte G, Hardikar W, Houwen RHJ, Kamath BM, Karpen SJ, Kjems L, Lacaille F, Lachaux A, Lainka E, Mack CL, Mattsson JP, McKiernan P, Ozen H, Rajwal SR, Roquelaure B, Shagrani M, Shteyer E, Soufi N, Sturm E, Tessier ME, Verkade HJ, Horn P. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022 Sep;7(9):830-842. doi: 10.1016/S2468-1253(22)00093-0. Epub 2022 Jul 1.

    PubMed 35780807

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing A4250 (odevixibat) in people with PFIC1 and PFIC2, run by Albireo at 45 sites in 15 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 14 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 45 sites in United States, Turkey (Türkiye), France, Germany, Israel and 10 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 5 Sep 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With at Least a 70% Reduction in Fasting Serum Bile Acid (s-BA) Concentration From Baseline to the End of Treatment or Reaching a Level <=70 Micromoles Per Liter (Mcmol/L) After 24 Weeks of Treatment (time frame: From Baseline (Day 1) up to Week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03566238, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in